Orbis Health Solutions

Orbis Health Solutions is a clinical-stage biotechnology company specializing in the development of personalized cancer immunotherapies. The company's proprietary TLPLDC (Tumor Lysate, Particle-Loaded, Dendritic Cell) platform creates autologous vaccines by loading a patient's own dendritic cells with their specific tumor lysate. This approach is designed to stimulate a robust and highly specific immune response against the unique neoantigens present in an individual's cancer. Orbis is currently evaluating its lead candidate in a Phase 2b/3 clinical trial for melanoma, with additional programs targeting lung and breast cancers. The company's mission is to provide effective, low-toxicity treatments that leverage the body's natural immune system to combat advanced malignancies.